首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   7861篇
  免费   1112篇
  国内免费   394篇
耳鼻咽喉   9篇
儿科学   66篇
妇产科学   19篇
基础医学   417篇
口腔科学   60篇
临床医学   881篇
内科学   575篇
皮肤病学   226篇
神经病学   293篇
特种医学   106篇
外科学   163篇
综合类   989篇
现状与发展   2篇
一般理论   2篇
预防医学   1600篇
眼科学   27篇
药学   2826篇
  8篇
中国医学   950篇
肿瘤学   148篇
  2024年   20篇
  2023年   188篇
  2022年   284篇
  2021年   425篇
  2020年   541篇
  2019年   377篇
  2018年   361篇
  2017年   370篇
  2016年   350篇
  2015年   356篇
  2014年   588篇
  2013年   641篇
  2012年   503篇
  2011年   540篇
  2010年   422篇
  2009年   373篇
  2008年   344篇
  2007年   298篇
  2006年   263篇
  2005年   308篇
  2004年   257篇
  2003年   196篇
  2002年   156篇
  2001年   137篇
  2000年   121篇
  1999年   77篇
  1998年   80篇
  1997年   78篇
  1996年   71篇
  1995年   76篇
  1994年   69篇
  1993年   78篇
  1992年   73篇
  1991年   63篇
  1990年   42篇
  1989年   59篇
  1988年   44篇
  1987年   24篇
  1986年   19篇
  1985年   25篇
  1984年   19篇
  1983年   8篇
  1982年   13篇
  1981年   6篇
  1980年   10篇
  1979年   2篇
  1978年   4篇
  1977年   3篇
  1976年   4篇
  1975年   1篇
排序方式: 共有9367条查询结果,搜索用时 15 毫秒
21.
介绍药学知识库内涵,分析建立药学知识库的必要性、意义、发展情况,从数据来源、模型构建、设计要点及应用几方面阐述其构建方法,提出未来发展方向。  相似文献   
22.
Background: Although China’s adverse drug reaction (ADR) reporting and monitoring has developed rapidly, many challenges remain. This study assessed ADR monitoring and reporting in China and identified monitoring problems.

Research design and methods: A cross-sectional survey was conducted of ADR reporting institutions in six Chinese provinces in April–December 2014. Questionnaires assessed ADR systems, basic resources, and pharmacovigilance activity.

Results: Of 720 questionnaires distributed, the response rate was 81.8%. About 93% (n = 371) of pharmaceutical companies and medical institutions had established ADR monitoring departments/units. Few institutions (26%, n = 104) allocated an ADR budget; 7% (n = 30) had received ADR monitoring funding in the last year (2013). Almost all institutions (99%, n = 555) had computers and 47% (n = 263) had a network database. Many institutions conducted public education about drug safety (49%, n = 283), medicine utilization reviews/quality surveys (28%, n = 158), and medicine consultation services (88%, n = 511). Institutions in eastern, central, and western China differed significantly on implementation of existing regulations and pharmacovigilance activities.

Conclusions: The institutions surveyed have established ADR monitoring systems. However, these systems have flaws. Urgent improvements are needed in funding, basic resources, reporting processes, and other pharmacovigilance activities.  相似文献   

23.
欧洲药品局(EMA)于2018年11月发布了"人用药品辅料右旋糖酐的包装说明书资料",该文件引用大量文献全面评价了右旋糖酐的安全性,特别指出含有右旋糖酐辅料的注射和吸入制剂的疫苗与药品,应在说明书中描述有关其过敏反应信息的新要求。介绍该文件的主要内容,期望对我国这类药品说明书的撰写和监管有所帮助。  相似文献   
24.
目的分析国家专利治疗化学性肝损伤的组方用药规律,为新药研发及相关专利的申请提供参考。方法以国家知识产权局中国专利公布公告网站收录的授权专利为资料来源,使用Microsoft Excel 2018建立数据库,对中药频次与分类进行统计分析;采用SPSS Statistic 21.0和SPSS Modeler 15.0对高频中药(频次≥10)进行性味归经分析、系统聚类分析、关联度与网络分析。结果纳入专利100项,涉及中药186味,以葛根最为常见;高频中药15味,药味以甘为主,药性以温、平为主,多归脾、肝经;聚类分析得到7组中药组合;二项、三项和四项关联规则分别为6、24、2项,各项组合分别为6、16、2项;核心药物为葛根、五味子、丹参、甘草、山楂、枸杞子、黄芪、柴胡、姜黄和枳椇子。结论中药复方治疗化学性肝损伤常用补虚、解表、化瘀、活血、渗湿及利水药;临证多采用疏肝理气之剂,适当伍以柔润之品。  相似文献   
25.
目的建立不同产地泽泻HPLC指纹图谱,并对其进行模式识别。方法泽泻乙腈提取物的分析采用Hanbon Hedera ODS-2 C18柱(250 mm×4.6 mm,5μm);流动相水-乙腈,梯度洗脱;柱温35℃;体积流量1.0 mL/min;检测波长210 nm。对结果进行化学模式识别(聚类分析、主成分分析和正交最小二乘法判别分析)。结果 19批四川产地样品指纹图谱中有17个共有峰,11批广西产地样品指纹图谱中12个共有峰,相似度均大于0.94。正交最小二乘法判别分析结合HPLC-MS/MS及对照品比对,筛选出泽泻醇B、泽泻醇A、11-去氧泽泻醇C、23-乙酰泽泻醇B、泽泻醇O、24-乙酰泽泻醇A6种主要差异性成分。结论该方法稳定可靠,可将四川、广西产地泽泻进行明显区分,从而用于该药材的质量控制与评价。  相似文献   
26.
《Neuromodulation》2021,24(8):1429-1438
IntroductionSphenopalatine ganglion (SPG) stimulation is an efficient treatment for cluster headache. The target for the SPG microstimulator in the pterygopalatine fossa lies between the vidian canal and foramen rotundum, ideally two contacts should be placed in this area. However, placement according to the manufacturers recommendations is frequently not possible. It is not known whether a suboptimal electrode placement interferes with postoperative outcomes.Materials and MethodsSPG stimulation was performed in 13 patients between 2015 and 2018 in a single center. Lead location was determined by intraoperative computed tomography scan and correlated with the planned lead position as well as clinical data and stimulation parameters. Patients with a reduction of 50% or more in pain intensity or frequency were considered responsive.ResultsEleven patients (84.6%) responded to SPG stimulation with eight being frequency responders (61.5%). In seven cases, there were less than two electrodes between vidian canal and foramen rotundum, there was no significant correlation with negative stimulation results (p = 0.91). The mean distance of lead location between pre- and postoperative images did not correlate with clinical outcomes (p = 0.84) and was even bigger in responders (4.91 mm vs. 4.53 mm). The closest electrode contact to the vidian canal was in the stimulation area in all but one patient, regardless of its overall distance to canal. The distance of the closest electrode to the vidian canal was, however, not significantly correlated to the percentage of frequency (p = 0.68) or intensity reduction (p = 0.61).ConclusionThere was no significant correlation regarding aberrations of lead position from the planned position with clinical outcome. However, this study might be underpowered to detect such a correlation. The closest electrode contact to the vidian canal was in the stimulation area in all but one patient in the final programming. This indicates that, overall, the lead location does play a crucial role in SPG stimulation for cluster headache.  相似文献   
27.
28.
经典名方泽泻汤的HPLC指纹图谱及多指标含量测定研究   总被引:2,自引:0,他引:2  
目的建立经典名方泽泻汤的HPLC指纹图谱,结合化学模式识别技术对其进行分析,并测定泽泻汤中3种成分23-乙酰泽泻醇B、23-乙酰泽泻醇C和白术内酯Ⅲ的含量,为泽泻汤质量控制提供科学依据。方法采用Waters WAT054275C18色谱柱(250 mm×4.6 mm,5μm),以乙腈-水为流动相进行梯度洗脱,建立15批泽泻汤的HPLC指纹图谱,并采用"中药色谱指纹图谱相似度评价系统"、SPSS22.0及SIMCA14.1软件对15批泽泻汤的HPLC指纹图谱进行相似度评价及聚类分析(CA)、偏最小二乘判别分析(PLS-DA)等化学模式识别。同时测定23-乙酰泽泻醇B、23-乙酰泽泻醇C和白术内酯Ⅲ的含量。结果建立了15批泽泻汤的HPLC指纹图谱,相似度均0.94,标定了18个共有峰,指认出3个色谱峰,分别为11号峰白术内酯Ⅲ、15号峰23-乙酰泽泻醇C、16号峰23-乙酰泽泻醇B,CA和PLS-DA将15批泽泻汤样品分为2类,同时15批泽泻汤中23-乙酰泽泻醇B、23-乙酰泽泻醇C和白术内酯Ⅲ的质量分数分别为0.321~0.569、0.075~0.139、0.106~0.142 mg/g。结论 HPLC指纹图谱结合多成分同时测定的方法,快速、简便、重复性好,为泽泻汤及其制剂的质量评价提供参考。  相似文献   
29.
BackgroundAs an ongoing worldwide health issue, Coronavirus disease 2019 (COVID–19) has been causing serious complications, including pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. However, there is no decisive treatment approach available for this disorder, which is primarily attributed to the large amount of inflammatory cytokine production. We aimed to identify the effects of Nano-curcumin on the modulation of inflammatory cytokines in COVID-19 patients.MethodForty COVID-19 patients and 40 healthy controls were recruited and evaluated for inflammatory cytokine expression and secretion. Subsequently, COVID-19 patients were divided into two groups: 20 patients receiving Nano-curcumin and 20 patients as the placebo group. The mRNA expression and cytokine secretion levels of IL-1β, IL-6, TNF-α and IL‐18 were assessed by Real‐time PCR and ELISA, respectively.ResultOur primary results indicated that the mRNA expression and cytokine secretion of IL-1β, IL-6, TNF-α, and IL-18 were increased significantly in COVID-19 patients compared with healthy control group. After treatment with Nano-curcumin, a significant decrease in IL-6 expression and secretion in serum and in supernatant (P = 0.0003, 0.0038, and 0.0001, respectively) and IL-1β gene expression and secretion level in serum and supernatant (P = 0.0017, 0.0082, and 0.0041, respectively) was observed. However, IL-18 mRNA expression and TNF-α concentration were not influenced by Nano-curcumin.ConclusionNano-curcumin, as an anti-inflammatory herbal based agent, may be able to modulate the increased rate of inflammatory cytokines especially IL-1β and IL-6 mRNA expression and cytokine secretion in COVID-19 patients, which may cause an improvement in clinical manifestation and overall recovery.  相似文献   
30.
为提高抗病毒药物在新型冠状病毒肺炎(COVID-19)患者尤其是需要多药联合患者中的合理性和安全性,结合《新型冠状病毒肺炎诊疗方案(试行第七版)》提到的抗病毒药物,通过查阅文献、搜集各抗病毒药物说明书和MCDEX合理用药信息支持系统的相关信息,总结这些抗病毒药物的临床药动学特征、药物相互作用及不良反应信息,提出合理的用药监护建议。从药动学和药物相互作用角度加强抗病毒药物在COVID-19患者中的用药监护,可提高药物使用安全性,保障患者的合理用药。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号